Plutux
$5.10
-4.49%
2026-08-31 16:00:00 EDT-$0.24
Healthcare
Biotechnology
NASDAQ
Active Trading

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, ...

Price Action

$5.10
-4.49%-$0.24
High
Low
52W High-46.1%
Rel. vol
Interval
Range2h
VolumeSMA5SMA10
ImageneBio Inc (NASDAQ: IMA) is a clinical-stage biotechnology company dedicated to developing novel therapeutics for patients with immunological, autoimmune, and inflammatory diseases. The company was originally founded as Inmagene in 2019 and became public via a reverse merger with Ikena Oncology in July 2025, forming ImageneBio. Headquartered in San Diego, ...ImageneBio Inc (NASDAQ: IMA) is a clinical-stage biotechnology company dedicated to developing novel therapeutics for patients with immunological, autoimmune, and inflammatory diseases. The company was originally founded as Inmagene in 2019 and became public via a reverse merger with Ikena Oncology in July 2025, forming ImageneBio. Headquartered in San Diego, California, the company is led by CEO Kristin Yarema, with co-founders Yanina Grant and Jonathan Wang. The company's primary focus is on advancing its lead asset, IMG-007, a non-depleting anti-OX40 monoclonal antibody designed to modulate T-cell responses in inflammatory diseases. IMG-007 is currently in Phase 2b clinical trials for atopic dermatitis, with topline data expected in Q4 2025. The company is also exploring other indications and pipeline candidates. As a clinical-stage biotech, ImageneBio has no approved products or revenue, and its financials reflect significant R&D investment. As of the latest data, the company has a market cap of approximately $63.3 million, with a cash position of about $8.42 per share and a strong current ratio of 21.47, indicating ample liquidity. The company employs 15 full-time employees and operates with a lean structure. ImageneBio aims to address significant unmet medical needs in immunology and inflammation, positioning itself as a potential leader in anti-OX40 therapies.
Founded
2019
Employees
18
CEO
Kristin Yarema
Full Name
ImageneBio Inc
Sector
Healthcare
Industry
Biotechnology
ROE
-38.99%
Market Cap
$0.06B
Current Ratio
21.47
WACC
6.94%
ROIC
-39.87%

Contact Information

858 345 6265
12526 High Bluff Drive, Suite 345, San Diego, CA 92130, San Diego, CA 92130

Related stocksBiotechnology

Browse all US stocks

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

© Plutux Technology Limited 2026